Studies show efficacy of rapastinel for treatment-resistant depression

Studies presented at the Society for Neuroscience Annual Meeting explored the antidepressant effects of rapastinel, an N-methyl-D-aspartate subtype of glutamate receptor modulator with characteristics of a glycine site partial agonist, currently in phase II clinical development for treatment-resistant depression. Researchers used hippocampal slices to evaluate the potential of pharmacological modulation of N-methyl-D-aspartate subtype of glutamate receptor (NMDAR) activity through the obligatory co-agonist binding site, its effect on modulation of the dissemination of cortical spreading depolarization and modulation of cortical spreading depolarization effects on dendritic spine morphology. Researchers found that rapastinel prevented induction of cortical spreading depolarization at times and when doing so, significantly slowed the rate of dissemination. In a subset of slices, primary cortical spreading depolarization triggered by “a focal puff of high [K+]” resulted in delayed, secondary cortical…


Link to Full Article: Studies show efficacy of rapastinel for treatment-resistant depression